IL155225A0 - Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders - Google Patents
Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disordersInfo
- Publication number
- IL155225A0 IL155225A0 IL15522501A IL15522501A IL155225A0 IL 155225 A0 IL155225 A0 IL 155225A0 IL 15522501 A IL15522501 A IL 15522501A IL 15522501 A IL15522501 A IL 15522501A IL 155225 A0 IL155225 A0 IL 155225A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- cognitive disorders
- inverse agonists
- combination use
- acetylcholinesterase inhibitors
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24114500P | 2000-10-17 | 2000-10-17 | |
| PCT/IB2001/001934 WO2002032412A2 (en) | 2000-10-17 | 2001-10-15 | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155225A0 true IL155225A0 (en) | 2003-11-23 |
Family
ID=22909428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15522501A IL155225A0 (en) | 2000-10-17 | 2001-10-15 | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20020151591A1 (https=) |
| EP (1) | EP1328294A2 (https=) |
| JP (1) | JP2004511512A (https=) |
| KR (1) | KR20030046509A (https=) |
| AR (1) | AR030893A1 (https=) |
| AU (2) | AU2001294117B2 (https=) |
| CA (1) | CA2426120A1 (https=) |
| HU (1) | HUP0302476A3 (https=) |
| IL (1) | IL155225A0 (https=) |
| NZ (1) | NZ525103A (https=) |
| PE (1) | PE20020473A1 (https=) |
| UY (1) | UY26970A1 (https=) |
| WO (1) | WO2002032412A2 (https=) |
| ZA (1) | ZA200302918B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| EP1585520A1 (en) * | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| WO2005027968A1 (ja) * | 2003-09-19 | 2005-03-31 | Eisai Co., Ltd. | ダウン症候群治療剤 |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
| JP2008509212A (ja) * | 2004-08-09 | 2008-03-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤 |
| CN100382802C (zh) * | 2005-08-08 | 2008-04-23 | 赵德禄 | 治疗自主神经系统功能紊乱的药物 |
| ES2573733T3 (es) | 2006-05-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Tratamiento farmacológico del deterioro cognitivo |
| JP5373613B2 (ja) | 2006-10-16 | 2013-12-18 | バイオノミクス リミテッド | 新規な抗不安薬化合物 |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP3034079B1 (en) | 2010-11-15 | 2018-01-10 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| CA2828780A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2707367B1 (en) | 2011-05-12 | 2019-10-09 | Bionomics Limited | Methods for preparing naphthyridines |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| JP6987384B2 (ja) | 2015-06-19 | 2021-12-22 | エージンバイオ， インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US11414425B2 (en) | 2018-06-19 | 2022-08-16 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| US5870723A (en) * | 1994-11-28 | 1999-02-09 | Pare, Jr.; David Ferrin | Tokenless biometric transaction authorization method and system |
| US6088683A (en) * | 1996-08-21 | 2000-07-11 | Jalili; Reza | Secure purchase transaction method using telephone number |
| US6016476A (en) * | 1997-08-11 | 2000-01-18 | International Business Machines Corporation | Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security |
| US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
| PL338783A1 (en) * | 1997-08-25 | 2000-11-20 | Neurogen Corp | Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
-
2001
- 2001-10-12 US US09/976,347 patent/US20020151591A1/en not_active Abandoned
- 2001-10-15 AU AU2001294117A patent/AU2001294117B2/en not_active Ceased
- 2001-10-15 WO PCT/IB2001/001934 patent/WO2002032412A2/en not_active Ceased
- 2001-10-15 IL IL15522501A patent/IL155225A0/xx unknown
- 2001-10-15 JP JP2002535650A patent/JP2004511512A/ja active Pending
- 2001-10-15 EP EP01974604A patent/EP1328294A2/en not_active Withdrawn
- 2001-10-15 NZ NZ52510301A patent/NZ525103A/xx unknown
- 2001-10-15 HU HU0302476A patent/HUP0302476A3/hu unknown
- 2001-10-15 KR KR10-2003-7005292A patent/KR20030046509A/ko not_active Ceased
- 2001-10-15 AU AU9411701A patent/AU9411701A/xx active Pending
- 2001-10-15 AR ARP010104836A patent/AR030893A1/es unknown
- 2001-10-15 CA CA002426120A patent/CA2426120A1/en not_active Abandoned
- 2001-10-16 PE PE2001001026A patent/PE20020473A1/es not_active Application Discontinuation
- 2001-10-16 UY UY26970A patent/UY26970A1/es not_active Application Discontinuation
-
2003
- 2003-04-11 ZA ZA200302918A patent/ZA200302918B/en unknown
-
2004
- 2004-08-06 US US10/912,993 patent/US20050009861A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20020473A1 (es) | 2002-06-14 |
| WO2002032412A2 (en) | 2002-04-25 |
| ZA200302918B (en) | 2004-04-13 |
| JP2004511512A (ja) | 2004-04-15 |
| US20050009861A1 (en) | 2005-01-13 |
| AU2001294117B2 (en) | 2006-07-27 |
| AU9411701A (en) | 2002-04-29 |
| NZ525103A (en) | 2004-12-24 |
| HUP0302476A3 (en) | 2005-05-30 |
| US20020151591A1 (en) | 2002-10-17 |
| HUP0302476A2 (hu) | 2003-11-28 |
| CA2426120A1 (en) | 2002-04-25 |
| EP1328294A2 (en) | 2003-07-23 |
| UY26970A1 (es) | 2002-06-20 |
| WO2002032412A3 (en) | 2003-03-20 |
| KR20030046509A (ko) | 2003-06-12 |
| AR030893A1 (es) | 2003-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL155225A0 (en) | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders | |
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| AU2002351397A8 (en) | Systems and methods using vasoconstriction for improved thermal treatment of tissues | |
| HUP0600103A2 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders | |
| HUP0104676A3 (en) | Compositions for the treatment of anorectal disorders and their use | |
| EP1392292A4 (en) | PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT | |
| AU5714601A (en) | Methods for prevention and treatment of gastrointestinal disorders | |
| SI1627639T1 (sl) | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj | |
| IL159313A0 (en) | Methods for treatment of cognitive and menopausal disorders with d-threo-methylphenidate | |
| IL162153A0 (en) | Methods and compositions for treatment of central nervous systemdisorders | |
| PL361947A1 (en) | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for treating of nervous systems disorders | |
| ZA200208228B (en) | Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis | |
| AU1202202A (en) | Methods for the treatment of cellular proliferative disorders | |
| PL350845A1 (en) | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | |
| IL156778A0 (en) | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders | |
| IL155874A0 (en) | Treatment of anxiety disorders | |
| EP1455780A4 (en) | NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | |
| IL140540A0 (en) | Treatment of anxiety disorders | |
| EP1539100A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS | |
| EP1315499A4 (en) | COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES | |
| IL151493A0 (en) | Use of dermaciclane for the treatment of anxiety and depression | |
| AU2000270300A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
| GB0010496D0 (en) | Treatment of conditions of the central nervous system | |
| IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith | |
| EP1440165A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELL PROLIFERATION DISORDERS USING 25943 |